AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7852551
Drug: Prophylaxis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis with ganciclovir for 2 weeks and then high-dose acyclovir for 2.5 months
Trial: 7852551
Drug: High-dose acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose acyclovir alone for 3 months
Trial: 1183220
Drug: Placebo (antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (antacid containing)
Trial: 18165598
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine + rofecoxib 50 mg
Trial: 18165598
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine + rofecoxib 50 mg
Trial: 16861092
Drug: Fentanyl effervescent
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl effervescent buccal tablet (FEBT) 100 microg
Trial: 16861092
Drug: Fentanyl effervescent
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl effervescent buccal tablet (FEBT) 200 microg
Trial: 16861092
Drug: Fentanyl effervescent
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl effervescent buccal tablet (FEBT) 400 microg
Trial: 16861092
Drug: Fentanyl effervescent
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl effervescent buccal tablet (FEBT) 800 microg
Trial: 15733521
Drug: Isosmotic polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosmotic polyethylene glycol 3350 electrolyte solution
Trial: 15733521
Drug: Isosmotic electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosmotic electrolyte solution
Trial: 7288563
Drug: Misattribution treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misattribution treatment (high-frequency noise)
Trial: 28763243
Drug: FS MDPI
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS MDPI 50/12.5 mcg
Trial: 28763243
Drug: FS MDPI
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FS MDPI 100/12.5 mcg
Trial: 28763243
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp MDPI 50 mcg
Trial: 28763243
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fp MDPI 100 mcg
Trial: 22017530
Drug: Y1 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Y1 antagonist (AR-H040922) during atenolol
Trial: 22017530
Drug: Y1 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Y1 antagonist (AR-H040922) during metoprolol
Trial: 21111318
Drug: Gas-forced infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gas-forced infusion (air pump)
Trial: 21111318
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no gas-forced infusion)
Trial: 16802774
Drug: Fluticasone propionate,
RxNorm normalized name: fluticasone propionate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate, 200 microg daily
Trial: 12594897
Drug: Acylaminopenicillin-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acylaminopenicillin-based therapy
Trial: 12594897
Drug: Cephalosporin-based antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalosporin-based antibiotic therapy
Trial: 6536768
Drug: Grief group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grief group therapy
Trial: 24762259
Drug: Hypocaloric diet
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric diet (6-months treatment)
Trial: 10852048
Drug: New concentrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New concentrated inactivated leptospirosis vaccine (0.5 ml, single injection)
Trial: 10852048
Drug: Existing commercial
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Existing commercial vaccine (2.0 ml and 2.5 ml, two injections)
Trial: 1710591
Drug: Hydroxyethyl-starch (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl-starch (250 ml daily) + Pentoxifylline (oral: 1200 mg/day; i.v.: 300 mg/day)
Trial: 1710591
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no hemodilution or rheological therapy)
Trial: 29155035
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 0.25% bupivacaine (treatment group)
Trial: 29155035
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL normal saline solution (control group)
Trial: 23102189
Drug: Fluticasone/formoterol 250/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol 250/10 μg twice daily
Trial: 23102189
Drug: Budesonide/formoterol 400/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 400/12 μg twice daily
Trial: 10320241
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (HCCs)
Trial: 1679626
Drug: Massed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massed treatment condition (shorter intersession intervals)
Trial: 1679626
Drug: Spaced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spaced treatment condition (longer intersession intervals)
Trial: 6627195
Drug: No preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preparation at all
Trial: 28128751
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution (NaCl)
Trial: 22113068
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of 100 g of blanched Agaricus bisporus white button mushroom daily for 1 week
Trial: 22113068
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily diet without WBM (control group)
Trial: 22113068
Drug: Dietary intake
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary intake of 100 g of blanched Agaricus bisporus white button mushroom
Trial: 19945492
Drug: Chickpea supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chickpea supplemented diet (average 104 g/day)
Trial: 17494881
Drug: Cyclophosphamide and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide and steroids (prednisolone) for 6 months
Trial: 17494881
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatment (control group)
Trial: 16327614
Drug: Preoperative single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative single intravenous dose of antibiotics
Trial: 16327614
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen with preoperative single-shot antibiotics plus a postoperative 7-day course of oral antibiotics
Trial: 11872885
Drug: Weight-based heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based heparin nomogram
Trial: 9495223
Drug: Stavudine 40
RxNorm normalized name: stavudine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 40 mg single oral dose
Trial: 2497168
Drug: Theophylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (300 mg, sustained-release, Theo-Dur)
Trial: 1092420
Drug: Intermittent positive-pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent positive-pressure ventilation (I.P.P.V.) of 10 mg of salbutamol
Trial: 1092420
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose (200 mug) from a pressurized canister
Trial: 447817
Drug: Melatonin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (250 mg every 8 h over a period of 40 h)
Trial: 31425700
Drug: 13 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 mg/day total MXans
Trial: 31425700
Drug: 27 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 27 mg/day total MXans
Trial: 30136102
Drug: Tramadol ER
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol ER 200 mg in the morning, 100 mg in the evening
Trial: 30136102
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of pregabalin 150 mg and tramadol ER 200 mg in the morning, and pregabalin 150 mg and tramadol ER 100 mg in the evening
Trial: 26728611
Drug: Etoricoxib (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (90 mg once daily for nine days)
Trial: 26728611
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg twice daily for nine days)
Trial: 25141536
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise with self-manual therapy
Trial: 25141536
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise without self-manual therapy
Trial: 17644512
Drug: Anti-anginal drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-anginal drug therapy in addition to risk factor control (MED)
Trial: 17644512
Drug: Anti-anginal drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-anginal drug therapy (MED)
Trial: 16227030
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g amino acids (AA)/(kg.d) from birth onward
Trial: 16227030
Drug: Glucose only
RxNorm normalized name: Glucose only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose only during the first day with a stepwise increase in AA intake to 2.4 g AA/(kg.d) on day 3
Trial: 10086669
Drug: Cisapride, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 10 mg q.i.d. for 4 days
Trial: 7648705
Drug: cA2, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2, a chimaeric anti-TNF-α monoclonal antibody (MoAb)
Trial: 31955940
Drug: Ultralong, 6.35-cm,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralong, 6.35-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters
Trial: 31955940
Drug: Standard long,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard long, 4.78-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters
Trial: 30845037
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of prophylactic antibiotics (n = 4,523)
Trial: 24386952
Drug: Concurrent cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent cetuximab and pemetrexed (Arm B)
Trial: 24386952
Drug: Cetuximab therapy
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab therapy
Trial: 7578729
Drug: Drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug regimen 1 (3 doses of 3-5 mg/kg, on days 0, 3, and 10)
Trial: 7578729
Drug: Drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug regimen 2 (6 doses of 3-5 mg/kg, on days 0, 3, 6, 8, 10, and 13)
Trial: 7578729
Drug: Rescue therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue therapy with L-AmB alone (3 mg/kg daily for 10 days)
Trial: 7578729
Drug: Regimen 3
RxNorm normalized name: Bayer Aspirin Regimen 325mg Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 3 (4 doses of 4-5 mg/kg, on days 0, 2, 5, and 7)
Trial: 7578729
Drug: Optimal regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal regimen of L-AmB
Trial: 2339368
Drug: F XIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F XIII concentrate administered within 6 hours after delivery
Trial: 565418
Drug: Isotonic amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic amino acid infusions
Trial: 565418
Drug: Preoperative keto-adaptation
RxNorm normalized name: Keto-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative keto-adaptation by a carbohydrate-free, oral protein diet
Trial: 565418
Drug: Postoperative amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative amino acid infusions only
Trial: 565418
Drug: 5 percent
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 percent dextrose infusions
Trial: 29315160
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (1200 IU)
Trial: 21912983
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment (2 Hz/32.4 mJ/5.9 J/cm(2))
Trial: 21912983
Drug: Er,Cr:YSGG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er,Cr:YSGG laser treatment (0.25 W/4.4 J/cm(2))
Trial: 21912983
Drug: Er,Cr:YSGG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er,Cr:YSGG laser treatment (0.50 W/8.9 J/cm(2))
Trial: 20523083
Drug: Platinum-based first-line
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based first-line chemotherapy
Trial: 20523083
Drug: Non-platinum-based first-line
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platinum-based first-line chemotherapy
Trial: 20523083
Drug: Platinum-based second-line
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based second-line chemotherapy
Trial: 20523083
Drug: Non-platinum-containing second-line
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-platinum-containing second-line chemotherapy
Trial: 16188050
Drug: Aspirin-sensitive group
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-sensitive group
Trial: 11813818
Drug: Quantitative CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative CT in the evaluation of patients with emphysema for surgery and drug therapy
Trial: 7554633
Drug: Enoxaparin 10
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 10 mg once daily
Trial: 7554633
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose unfractionated heparin (5000 IU 3 times daily or 7500 IU twice daily)
Trial: 7554633
Drug: Enoxaparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (30 mg twice daily, 40 mg once daily, 10 mg once daily)
Trial: 373841
Drug: Cephaloridine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephaloridine (3 doses, continued for 12 hours post-surgery)
Trial: 28639118
Drug: T0001 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T0001 (10, 20, 35, 50, 65, or 75 mg)
Trial: 23725215
Drug: Long-acting beta-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta-agonists
Trial: 12755836
Drug: H2-receptor antagonist
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonist (300 mg nizatidine)
Trial: 12755836
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (30 mg lansoprazole)
Trial: 12755836
Drug: H2-receptor antagonists
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonists (overall efficacy from 12 studies)
Trial: 12755836
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (overall efficacy from 12 studies)
Trial: 12755836
Drug: H2-receptor antagonist
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonist (clarithromycin-containing regimens)
Trial: 12755836
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (non-clarithromycin-containing trials)
Trial: 9071052
Drug: Caffeine, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine, dosage and duration not specified
Trial: 7529464
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (2 million units loading dose, 2 million units added to the CPB prime, and 500,000 units/hr maintenance infusion)
Trial: 3164442
Drug: Intravenous gammaglobulin
RxNorm normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gammaglobulin (ivGG) infusion
Trial: 23672818
Drug: Atomoxetine once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine once daily (n = 32)
Trial: 18972727
Drug: Scalp-acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp-acupuncture plus exercise therapy
Trial: 11008326
Drug: L-Tryptophan (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Tryptophan (500 mg)
Trial: 1673628
Drug: CV 205‐502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV 205‐502 (0.075 mg once daily)
Trial: 31519130
Drug: Hyperfractionated, Accelerated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated, Accelerated Radiotherapy (HART) prescribed as 76 Gy in 56 fractions, 10 fractions weekly; no chemotherapy
Trial: 21551510
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg twice a day
Trial: 15195061
Drug: Topical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mitomycin C applied to the intact tympanic membrane
Trial: 7859799
Drug: Lifibrol 150
RxNorm normalized name: Lifibrol
DrugBank: Lifibrol (DB12448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifibrol 150 mg/day
Trial: 7859799
Drug: Lifibrol 300
RxNorm normalized name: Lifibrol
DrugBank: Lifibrol (DB12448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifibrol 300 mg/day
Trial: 7859799
Drug: Lifibrol 450
RxNorm normalized name: Lifibrol
DrugBank: Lifibrol (DB12448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifibrol 450 mg/day
Trial: 7859799
Drug: Lifibrol 600
RxNorm normalized name: Lifibrol
DrugBank: Lifibrol (DB12448)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifibrol 600 mg/day
Trial: 7859799
Drug: Lifibrol (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifibrol (high baseline levels > 30 mg.dl-1)
Trial: 31600432
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation Treatment for Depression (BATD), 12 sessions
Trial: 21154218
Drug: Ketamine (0.23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.23 mg/kg bolus followed by 0.64 mg/kg/h)
Trial: 10696840
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment for large adenomas and early colorectal cancer
Trial: 26771854
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for recurrent vestibular schwannoma (Group A: previously operated on and received postoperative radiosurgery; Group B: previously operated on but did not receive postoperative radiosurgery)
Trial: 26771854
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for recurrent vestibular schwannoma (Group A and B)
Trial: 26771854
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for recurrent vestibular schwannoma
Trial: 23214247
Drug: CCS combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCS combined with NBT and YB capsules
Trial: 20164307
Drug: Lysine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine intake of 104.9 mg . kg(‐1) . d(‐1)
Trial: 20164307
Drug: Lysine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine intake of 117.6 mg . kg(‐1) . d(‐1)
Trial: 17515572
Drug: Trastuzumab 4
RxNorm normalized name: TRASTUZUMAB 440MG/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab 4 mg/kg (day 1), followed by 2 mg/kg weekly, plus docetaxel 75 mg/m2 every 3 weeks, and carboplatin (area under curve, 6) for six cycles before surgery
Trial: 17515572
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy (docetaxel and carboplatin)